Arcturus Therapeutics Holdings Inc ARCT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
-
Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
-
Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis
-
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
-
Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress
-
Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference
-
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024
-
Arcturus Therapeutics Gets FDA Orphan Designation for ARCT-032 in Cystic Fibrosis
Trading Information
- Previous Close Price
- $21.77
- Day Range
- $21.74–22.37
- 52-Week Range
- $17.52–45.00
- Bid/Ask
- $20.00 / $22.37
- Market Cap
- $595.74 Mil
- Volume/Avg
- 185 / 437,987
Key Statistics
- Price/Earnings (Normalized)
- 8.41
- Price/Sales
- 4.02
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 180
- Website
- https://www.arcturusrx.com
Comparables
Valuation
|
Metric
|
ARCT
|
HRTX
|
TERN
|
|---|---|---|---|
Price/Earnings (Normalized) | 8.41 | — | — |
Price/Book Value | 2.30 | — | 2.75 |
Price/Sales | 4.02 | 2.25 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ARCT
HRTX
TERN
Financial Strength
|
Metric
|
ARCT
|
HRTX
|
TERN
|
|---|---|---|---|
Quick Ratio | 3.10 | 1.76 | 20.57 |
Current Ratio | 3.78 | 2.38 | 21.02 |
Interest Coverage | −3,734.00 | — | — |
Quick Ratio
ARCT
HRTX
TERN
Profitability
|
Metric
|
ARCT
|
HRTX
|
TERN
|
|---|---|---|---|
Return on Assets (Normalized) | −9.87% | −11.68% | −28.87% |
Return on Equity (Normalized) | −15.36% | — | −30.36% |
Return on Invested Capital (Normalized) | −18.47% | −18.15% | −34.37% |
Return on Assets
ARCT
HRTX
TERN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Zwcmjqsdv | Pmgxr | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Dhmxcxkk | Kpsjd | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Kbbhgcbq | Rtmypl | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Dlbyyywc | Ybvmh | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Gdrprcr | Ntmf | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Bzxhjsv | Cxkl | $28.1 Bil | |||
| Moderna Inc
MRNA
| Frmhysll | Wtdq | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Dvgzvszwl | Wyqfj | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Zzwdhqkv | Rydbyk | $13.4 Bil | |||
| Incyte Corp
INCY
| Xsrbrdm | Xjrlzf | $12.7 Bil |
United States